Oncology

Discover how SITC’s innovative strategies are transforming clinical trials to accelerate the development and approval of cancer immunotherapies, aiming for 100 new treatments in the next decade.

Women experiencing housing insecurity are significantly less likely to receive routine breast cancer screening, according to a new study analyzing Medicaid beneficiaries in Pennsylvania.

The widespread overuse of adrenal CT scans, revealing that more than half of these imaging studies are performed unnecessarily, has been investigated in a new study.

A new post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).

Patients recovering from lung cancer surgery may face prolonged hospital stays when wildfires strike, according to new research examining the effects of wildfire disasters on post-operative recovery.

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

In a pivotal development for the oncology community, a recent retrospective study has demonstrated that continuing immunotherapy beyond disease progression offers significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).